2008
DOI: 10.1080/08956308.2008.11657534
|View full text |Cite
|
Sign up to set email alerts
|

Identify Your Innovation Enablers and Inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
9
0
3

Year Published

2010
2010
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 7 publications
1
9
0
3
Order By: Relevance
“…Innovation plays a vital role in today's rapidlychanging business environment (Von, 2007(Von, , 2005. Nowadays, most of the literatures support that innovation means "rewiring organizations for creativity and growth" (Balsano et al, 2008;McGregor, 2006). Manufacturing Sector is the main engine of economic growth and wealth creator for a country; it creates a sustainable economic, encourages investments, creates jobs and builds the nation.…”
Section: Introductionmentioning
confidence: 98%
“…Innovation plays a vital role in today's rapidlychanging business environment (Von, 2007(Von, , 2005. Nowadays, most of the literatures support that innovation means "rewiring organizations for creativity and growth" (Balsano et al, 2008;McGregor, 2006). Manufacturing Sector is the main engine of economic growth and wealth creator for a country; it creates a sustainable economic, encourages investments, creates jobs and builds the nation.…”
Section: Introductionmentioning
confidence: 98%
“…This context has been the attention of focus with the literature on innovation because the pharmaceutical industry, possibly more than any other, depends on innovation for success: ‘The key to long‐term growth has to be R&D pipeline success’ (McNamara, , p. 25). Within extant literature researchers have used case studies of firms from the pharmaceutical industry to gauge cultural enablers supporting innovation (Balsano et al., ), and to divide the new product innovation process into two distinct phases of early and late‐stage development (Bonabeau et al., ). Within the pharma industry, decisions often need to be made based on insufficient data and with a high degree of uncertainty, acute time pressure, in an environment where decisions are costly (clinical trials, etc.)…”
Section: Methodsmentioning
confidence: 99%
“…From an organizational perspective seven enablers were identified, i.e. collaboration (Aagard & Gertsen, 2011;López-Fernández and Serrano-Bedina, 2011;Ross et al, 2012;West et al, 2004;Yu, 2010, culture (Aagard & Gertsen, 2011Balsamo et. al., 2008;Denti and Hemlin, 2012;Smith et al, 2008;Yu, 2010, education (Aagard & Gertsen, 2011West et al, 2004;Yu, 2010), knowledge (Aagard & Gertsen, 2011;López-Fernández and Serrano-Bedina, 2011;Ross et al, 2012), management (Aagard & Gertsen, 2011;Denti and Hemlin, 2012;Gambatese and Hallowell (2011); López-Fernández and Serrano-Bedina, 2011;Smith et al, 2008), strategy Aagard & Gertsen, 2011, Manley, 2006Smith et al, 2008) and structure (Denti and Hemlin, 2012;Gambatese and Hallowell (2011); López-Fernández and Serrano-Bedina, 2011;Smith et al, 2008;Yu, 2010).…”
Section: Previous Knowledge On Innovation Enablersmentioning
confidence: 99%